Novel PI3K/Akt Inhibitors Screened by the Cytoprotective Function of Human Immunodeficiency Virus Type 1 Tat A Novel Screening System for PI3K/Akt Inhibitors
2011
Screening for New HIV Treatments Using a Cell Model
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Kim Yuri, Hollenbaugh Joseph A., Kim Dong-Hyun, Kim Baek
Hypothesis
The cytoprotective effect of HIV-1 Tat protein can be exploited to screen for novel PI3K/Akt inhibitors.
Conclusion
Three novel compounds were identified that can inhibit the cytoprotective effect of HIV-1 Tat in a human cell model.
Supporting Evidence
- The study identified Lancemaside A1, Compound K, and Arctigenin as effective inhibitors of the PI3K/Akt pathway.
- Tat-expressing CHME5 cells showed a significantly lower baseline cell death compared to control cells.
- The compounds were shown to target different steps of the PI3K/Akt signaling pathway.
Takeaway
Researchers found three new drugs that can help fight HIV by stopping infected cells from surviving too long.
Methodology
The study used a human microglial cell line expressing HIV-1 Tat to screen for compounds that inhibit the PI3K/Akt pathway.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website